Overview

Arterial Disease Multifactorial Intervention Trial (ADMIT)

Status:
Completed
Trial end date:
1999-03-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Beta Carotene
Carotenoids
Pravastatin
Vitamin E
Vitamins
Warfarin
Criteria
Men and women with symptomatic or asymptomatic peripheral arterial disease.